Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Left-sided tumors with wild-type KRAS had greater proportion of liver metastasis (78.6% versus 53.5%, P = 0.00), whereas those with mutant KRAS had greater proportion of lung metastasis (23.3% versus 8.7%, P = 0.02). 30737098 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE KRAS mutation was detected in 23/45 cases using ct-DNA (liver or lung metastasis, 18/19; mutation allele frequency [MAF], 0.1-31.7%; peritoneal metastasis, 3/9 [0.1%], locally advanced, 2/17 [0.1-0.2%]). 31746520 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Of the mutations in PMs, 71% (22/31) were KRAS G>A transitions, of which 82% (18/22) were KRAS G12D or G13D. 31773354 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE We focused on patients exhibiting 1 lung metastasis who underwent an AR (segmentectomy) or an NAR (wedge) and for whom the KRAS mutational status was known. 29781848 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Methods The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon cancer in patients who underwent SABR; patients receiving previous chemotherapy alone or in combination with bevacizumab; Karnofsky performance status >80; life expectancy >6 months; at least 6 months' follow-up after SABR; presence of KRAS mutation. 29737958 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Prospective multicenter studies are necessary to fully understand the prognostic value of KRAS mutations in the lung metastases of CRC. 27911859 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE KRAS mutation exists in about 40% CRC, associated with higher cumulative incidence of CRC lung metastasis, and acts as an independent predictor of metastasis to lung. 27590223 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Multivariate analysis showed that  primary tumor location (OR 3.92, p = 0.07) and KRAS mutation (OR 2.45, p = 0.09) were significant factors in lung metastasis model. 28161825 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Analysis of KRAS mutation combined with immunohistochemical expression of CD44 and CD166 identified subgroups of patients with colon adenocarcinoma at higher risk of lymph node involvement by the tumor and development of liver and lung metastasis. 27062566 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. 26887348 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE Sixty-four percent of patients had KRAS WT lung metastases.PTEN loss-of-function was found in 75%. 26715198 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Overall, the prevalence of KRAS exon 2 was 36.8%, and it was lower in liver metastases (N = 138/490; 28.2%) in comparison with primary tumors (N = 442/1086; 40.7%), lung metastases (16/32; 50%), or other metastatic sites (15/51; 29.4%; P < 0.0001). 25420993 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Lung metastasis was more likely to develop during the disease course in patients whose tumour had a KRAS mutation than in those whose tumour did not have a KRAS mutation. 25535726 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE NRAS and KRAS mutated tumors did not show significant differences in terms of clinical and pathological characteristics, except for a lower prevalence of mucinous histology (p = 0.012) and lung metastases (p = 0.012) among NRAS mutated tumors. 24806288 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE To better understand the impact of KRAS mutation subtype, we analyzed data from 677 patients with KRAS mutant metastatic lung cancer. 25415430 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). 25888291 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Brain and lung metastases had higher KRAS mutations than other sites (65% vs 59% vs 47%, respectively, p = 0.07, <0.01), suggesting poor response to anti-EGFR therapies. 26553611 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 AlteredExpression disease BEFREE More important, the inhibition of the Kras gene expression in gastric tumors prevents the occurrence of metastasis to lung (80% reduction), increasing mice survival in more than 85%. 26189409 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Lung metastases were more common in both the KRAS 12/13-mutated and atypical RAS-mutated cohorts relative to patients with RAS/BRAF wild-type tumors. 25009008 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 AlteredExpression disease BEFREE We observed that the K-Ras-ERK pathway is important for the expression of genes associated with the lung metastasis signature. 23995792 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE The cumulative incidence of bone, brain, and lung metastases was significantly higher for patients with KRAS MUT compared with those with KRAS WT. 25155157 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE Moreover, KRAS Mts were associated with the number of PMs (p = 0.037) and with the lung as first site of recurrence after metastasectomy (p = 0.047). 24281417 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE There were no significant differences in epidermal growth factor receptor or KRAS mutations by gender or primary versus metastatic lung cancer. 22666783 2012
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE Compared with primary tumor sites, the KRAS discordance rate was significantly higher in matched lung metastases [32.4% (12/37)] than in other matched metastatic organs (P = 0.005). 22876814 2012
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Bivariate analyses demonstrated significant differences between KRAS wild-type, codon 12-mutated, and codon 13-mutated tumors with regard to synchronous lymph node metastasis (P=0.018), organ metastasis (76.8% vs. 65.9% vs. 89.5%, P=0.009), liver metastasis (89.5% vs. 78.2% vs. 92.1%, P=0.025), lung metastasis (29.5% vs. 42.9% vs. 50%, P=0.041), liver-only metastasis (48.4% vs. 28.8% vs. 28.9%, P=0.006), and metastases in two or more organs (49.5, 61.4, 71.1, P=0.047). 21795973 2011